摘要
目的探究艾迪注射液联合PD方案(培美曲塞PEM+顺铂DDP)治疗晚期肺腺癌的疗效。方法选取我院已病理确诊的80例晚期肺腺癌患者,随机分为观察组(40例,艾迪注射液+PD方案治疗)和对照组(40例,PD方案治疗)。结果观察组与对照组治疗有效率分别为32.5%,25.0%,差异无统计学意义(P>0.05),而观察组临床获益率(95.0%)明显高于对照组(75.0%),差异有统计学意义(P<0.05);观察组血小板减少的发生率显著低于对照组,差异有统计学意义(P<0.05);观察组生活质量改善率60.0%,显著高于对照组32.5%,差异有统计学意义(P<0.05);观察组体重"上升"、"下降"差异均有统计学意义(P<0.05)。结论艾迪注射液联合PD方案能提高晚期肺腺癌患者化疗疗效、降低化疗毒性反应,促进体重增加,改善患者生活质量,值得临床参考应用。
Objective To explore the efficacy of Aidi injection combined with PD regimen（PEM＋DDP） in treating patients with advanced lung adenocarcinoma.Methods Eighty cases of advanced lung adenocarcinoma patients diagnosed by pathology were randomly divided into observation group（40 cases,Aidi injection plus PD regimen treatment） and control group（40 cases,PD regimen treatment）.Results The overall response rate of observation group and control group were 32.5% and 25.0%,with no significant differences observed（P〈0.05）,while the clinical benefit rate was significantly higher in observation group than control group,with statistical differences（95.0% vs75.0%,P〈0.05）.The incidence of platelet in the observation group was significantly lower than that in the control group,with statistical differences（P〈0.05）;The improvement rate of quality of life in the observation group was 60%,significantly higher than that in the control group（32.5%）,with statistical differences（P〈0.05）;The observation group in the weight ＂up＂ ＂down＂ differences were statistically significant（P〈0.05）.Conclusion Aidi injection combined with PD regimen can improve the efficacy of chemotherapy in patients with advanced lung adenocarcinoma,reduce the toxicity of chemotherapy,promote weight gain,and improve the quality of life of patients,it is worthy of clinical application.
出处
《潍坊医学院学报》
2017年第2期93-95,共3页
Acta Academiae Medicinae Weifang
关键词
艾迪注射液
培美曲塞
顺铂
肺腺肿瘤
Aidi injection
Pemetrexe
Cisplatin
Lung adenocarcinoma
